DR39 DataRelease

SDY1352: INDIGO HLA and KIR part 1
Status: New
Description: High resolution HLA and KIR typing in five CNS-related diseases.
Program/Contract:
ProgramContract
HLA and KIR Region Genomics in Immune-Mediated Diseases RFA-AI-14-012, RFA-AI-14-013 Immunogenetic Determinants Of Disease Risk In Neurological Disease Former grant ID: AI119350
DOI: 10.21430/M38ED12JYE
Subjects: 8708
Study PI, contact:
NameOrganizationSite
Jorge Oksenberg UCSF UCSF
Marcelo Fernandez-Via Stanford University Stanford University
Jill Hollenbach UCSF UCSF
Paul Norman University of Colorado-Denver University of Colorado-Denver
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
HLA Typing 8705
KIR Typing 3943
Clinical Assessments:None

SDY1613: Paired Heavy and Light Chain Immunoglobulin Reconstruction in Single-Cell RNA-Seq Data
Status: New
Description: We generated scRNA-Seq data for 20 human plasmablasts induced by seasonal flu vaccination.To reconstruct the paired heavy and light chain antibody genes, we developed several different in silico filtering strategies to enrich immunoglobulin transcripts, and then applied de novo assembly. This method successfully reconstructed productive IgH and IgL chains in 100% of cells analyzed. The accuracy of clonotype-assignment of individual cells was 94.5-98%, as validated by comparing BCR sequences reconstructed from NGS to those obtained by conventional single-B cell cloning methodology. This makes it possible to link the transcriptional programming of individual B cell clones at critical developmental stages with the eventual fate of the clonal lineage in vivo.
Program/Contract:
ProgramContract
Development of Sample Sparing Assays for Monitoring Immune Responses RFA-AI-14-027 SIMULTANEOUS ANTIGEN RECEPTOR REPERTOIRE PROFILING AND SINGLE-CELL TRANSCRIPTOMICS IN T AND B LYMPHOCYTES FROM LIMITED CLINICAL SAMPLES
DOI: 10.21430/M351ZMQT4J
Subjects: 3
Study PI, contact:
NameOrganizationSite
Steven Bosinger Emory University Emory University
Publications:
BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data.. Genome medicine Mar 2018. doi: 10.1186/s13073-018-0528-3 [Pubmed: 29558968]
Resources:
SRA https://www.ncbi.nlm.nih.gov/sra/?term=SRP126429]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 245
Clinical Assessments:None

SDY1689: Safety groups 1A & 1B: Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium falciparum NF54
Status: New
Description: A Phase 1 randomized, double blind, placebo-controlled trial to assess the safety, immunogenicity and tolerability of cryopreserved radiation attenuated Pf NF54 sporozoites (PfSPZ Vaccine) via direct venous inoculation (DVI) at increasing doses and assess the vaccine efficacy (VE) against naturally occurring infection in the main phase arms and controlled human malaria infection (CHMI) with PfSPZ Challenge (live Pf NF54 sporozoites) in the pilot phase arms of healthy African adults. After establishing safety of PfSPZ Vaccine in a pilot group (n=10), safety and efficacy was assessed by CHMI in 30 subjects who subjects received either 3 doses of PfSPZ Vaccine after pretreatment with artesunate amodiaquine (n=15) or without pretreatment (n=15). Results of CHMI was compared to 15 infectivity controls. Following the pilot studies, a randomized, double-blinded, placebo-controlled trial of safety and VE was conducted in 120 Malian adults with PfSPZ Vaccine (n=60) or normal saline (NS) placebo (n=60). VE was assessed by detection of Pf by thick blood smear (TBS) every 2 weeks or in response to symptomatic illness for 24 weeks after the last dose of vaccine or NS.
Program/Contract:
ProgramContract
DMID Sanaria Grant Program Genome-Wide Sieve Analysis And Immunological Validation To Identify Targets Of Protective Efficacy In Field Trials Of A Whole-Organism Malaria Vaccine
DOI: 10.21430/M3TNVQXR7I
Subjects: 10
Study PI, contact:
NameOrganizationSite
Mahamadou Sissoko University of Sciences, Techniques and Technology, Bamako Mali, West Africa
Patrick Duffy LMIV/NIAID/NIH Mali, West Africa
Publications:
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.. Human vaccines Jan 2010. doi: 10.4161/hv.6.1.10396 [Pubmed: 19946222]
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.. Science (New York, N.Y.) Sep 2013. doi: 10.1126/science.1241800 [Pubmed: 23929949]
Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.. Malaria journal Mar 2015. doi: 10.1186/s12936-015-0628-0 [Pubmed: 25889522]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02627456]
Assays:None
Clinical Assessments:None

SDY1690: Vaccine Safety and Placebo Groups Arm 1C & 1D with CHMI: Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium falciparum NF54
Status: New
Description: A Phase 1 randomized, double blind, placebo-controlled trial to assess the safety, immunogenicity and tolerability of cryopreserved radiation attenuated Pf NF54 sporozoites (PfSPZ Vaccine) via direct venous inoculation (DVI) at increasing doses and assess the vaccine efficacy (VE) against naturally occurring infection in the main phase arms and controlled human malaria infection (CHMI) with PfSPZ Challenge (live Pf NF54 sporozoites) in the pilot phase arms of healthy African adults. After establishing safety of PfSPZ Vaccine in a pilot group (n=10), safety and efficacy was assessed by CHMI in 30 subjects who subjects received either 3 doses of PfSPZ Vaccine after pretreatment with artesunate amodiaquine (n=15) or without pretreatment (n=15). Results of CHMI was compared to 15 infectivity controls. Following the pilot studies, a randomized, double-blinded, placebo-controlled trial of safety and VE was conducted in 120 Malian adults with PfSPZ Vaccine (n=60) or normal saline (NS) placebo (n=60). VE was assessed by detection of Pf by thick blood smear (TBS) every 2 weeks or in response to symptomatic illness for 24 weeks after the last dose of vaccine or NS.
Program/Contract:
ProgramContract
DMID Sanaria Grant Program Genome-Wide Sieve Analysis And Immunological Validation To Identify Targets Of Protective Efficacy In Field Trials Of A Whole-Organism Malaria Vaccine
DOI: 10.21430/M3TSUAJ9MA
Subjects: 45
Study PI, contact:
NameOrganizationSite
Mahamadou Sissoko University of Sciences, Techniques and Technology, Bamako Mali, West Africa
Patrick Duffy LMIV/NIAID/NIH Mali, West Africa
Publications:
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.. Human vaccines Jan 2010. doi: 10.4161/hv.6.1.10396 [Pubmed: 19946222]
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.. Science (New York, N.Y.) Sep 2013. doi: 10.1126/science.1241800 [Pubmed: 23929949]
Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.. Malaria journal Mar 2015. doi: 10.1186/s12936-015-0628-0 [Pubmed: 25889522]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02627456]
Assays:None
Clinical Assessments:None

SDY1691: Vaccine Efficay and Placebo Cohorts with Malaria Natural History Groups 2 & 3: Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium falciparum NF54
Status: New
Description: A Phase 1 randomized, double blind, placebo-controlled trial to assess the safety, immunogenicity and tolerability of cryopreserved radiation attenuated Pf NF54 sporozoites (PfSPZ Vaccine) via direct venous inoculation (DVI) at increasing doses and assess the vaccine efficacy (VE) against naturally occurring infection in the main phase arms and controlled human malaria infection (CHMI) with PfSPZ Challenge (live Pf NF54 sporozoites) in the pilot phase arms of healthy African adults. After establishing safety of PfSPZ Vaccine in a pilot group (n=10), safety and efficacy was assessed by CHMI in 30 subjects who subjects received either 3 doses of PfSPZ Vaccine after pretreatment with artesunate amodiaquine (n=15) or without pretreatment (n=15). Results of CHMI was compared to 15 infectivity controls. Following the pilot studies, a randomized, double-blinded, placebo-controlled trial of safety and VE was conducted in 120 Malian adults with PfSPZ Vaccine (n=60) or normal saline (NS) placebo (n=60). VE was assessed by detection of Pf by thick blood smear (TBS) every 2 weeks or in response to symptomatic illness for 24 weeks after the last dose of vaccine or NS.
Program/Contract:
ProgramContract
DMID Sanaria Grant Program Genome-Wide Sieve Analysis And Immunological Validation To Identify Targets Of Protective Efficacy In Field Trials Of A Whole-Organism Malaria Vaccine
DOI: 10.21430/M3CI9DVM22
Subjects: 120
Study PI, contact:
NameOrganizationSite
Mahamadou Sissoko University of Sciences, Techniques and Technology, Bamako Mali, West Africa
Patrick Duffy LMIV/NIAID/NIH Mali, West Africa
Publications:
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.. Human vaccines Jan 2010. doi: 10.4161/hv.6.1.10396 [Pubmed: 19946222]
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.. Science (New York, N.Y.) Sep 2013. doi: 10.1126/science.1241800 [Pubmed: 23929949]
Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.. Malaria journal Mar 2015. doi: 10.1186/s12936-015-0628-0 [Pubmed: 25889522]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02627456]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 226
Fluorescent Antibody Procedure 225
Neutralizing Antibody Titer Assay 224
Clinical Assessments:None

SDY1700: Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children
Status: New
Description: KSPZV1 is a single center study conducted in 2 parts. Part 1 is an age de-escalating, dose-escalating, randomized, double-blind, placebo-controlled trial enrolling malaria-exposed Kenyan children ages 5 months to 9 years at the time of first vaccination. One or two doses of the radiation-attenuated sporozoite-based PfSPZ Vaccine (8 per group) or normal saline placebo (4 per group) were administered by DVI at up to 5 different dosing levels using a staggered, dose-escalating design. Dosages include: 1.35 x10^5, 2.7 x10^5 (lowest two doses only in the two younger age groups), 4.5 x10^5, 9.0 x10^5, and 1.8 x10^6 PfSPZ in 13 cohorts of 12 participants each (3 dose cohorts among 5?9-year-olds, 5 among 1?5-year-olds, and 5 among 5?12-month-olds). Part 2 is a randomized, placebo controlled, double blind study in 5-12 month olds comparing the 3 highest does of PfSPZ Vaccine that are tolerated in part 1 (4.5 x10^5, 9.0 x10^5, and 1.8 x10^6 PfSPZ) with a normal saline placebo (randomized 1:1:1:1) to evaluate the safety , tolerability, immunogenicity and vaccine efficacy.
Program/Contract:
ProgramContract
DMID Sanaria Grant Program Genome-Wide Sieve Analysis And Immunological Validation To Identify Targets Of Protective Efficacy In Field Trials Of A Whole-Organism Malaria Vaccine
DOI: 10.21430/M3LMDEGZ3W
Subjects: 165
Study PI, contact:
NameOrganizationSite
Martina Oneko Kenya Medical Research Institute Kenya Medical Research Institute
Publications:
Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Aug 2020. doi: 10.1093/cid/ciz925 [Pubmed: 31555824]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=&term=NCT02687373]
Assays:None
Clinical Assessments:None

SDY1711: Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children
Status: New
Description: KSPZV1 is a single center study conducted in 2 parts. Part 1 is an age de-escalating, dose-escalating, randomized, double-blind, placebo-controlled trial enrolling malaria-exposed Kenyan children ages 5 months to 9 years at the time of first vaccination. One or two doses of the radiation-attenuated sporozoite-based PfSPZ Vaccine (8 per group) or normal saline placebo (4 per group) were administered by DVI at up to 5 different dosing levels using a staggered, dose-escalating design. Dosages include: 1.35 x10^5, 2.7 x10^5 (lowest two doses only in the two younger age groups), 4.5 x10^5, 9.0 x10^5, and 1.8 x10^6 PfSPZ in 13 cohorts of 12 participants each (3 dose cohorts among 5?9-year-olds, 5 among 1?5-year-olds, and 5 among 5?12-month-olds). Part 2 is a randomized, placebo controlled, double blind study in malaria exposed infants ages 5-12 months, comparing the 3 highest does of PfSPZ Vaccine that are tolerated in part 1 (4.5 x10^5, 9.0 x10^5, and 1.8 x10^6 PfSPZ) with a normal saline placebo (randomized 1:1:1:1) to evaluate the safety , tolerability, immunogenicity and vaccine efficacy.
Program/Contract:
ProgramContract
DMID Sanaria Grant Program Genome-Wide Sieve Analysis And Immunological Validation To Identify Targets Of Protective Efficacy In Field Trials Of A Whole-Organism Malaria Vaccine
DOI: 10.21430/M3EJ9N4NC2
Subjects: 336
Study PI, contact:
NameOrganizationSite
Martina Oneko Kenya Medical Research Institute Kenya Medical Research Institute
Publications:
Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Aug 2020. doi: 10.1093/cid/ciz925 [Pubmed: 31555824]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=&term=NCT02687373]
Assays:None
Clinical Assessments:None

SDY1715: A Retrospective Multicenter study to Determine Up to 5 Year Clinical Outcomes in Subjects Previously Randomized in the CTOT-11 Study (CTOT-23)
Status: New
Description: This study is a multicenter, non-randomized, retrospective, chart review study to collect long term (3 to 5 years post-transplant +/- 8 months) clinical outcome data on subjects previously enrolled in the CTOT-11 study. The CTOT-11 study randomized 163 subjects from September 2011 to September 2014. Eleven subjects withdrew consent, were lost to follow up, or died over the study period, and will not be included in the CTOT-23 study. This study will include up to 152 subjects. This study will be completed no later than December 2017. Each center will complete a retrospective chart review for the selected clinical variables identified in the Schedule of Events (Appendix 1), and enter the data in the Statistical and Clinical Coordinating Center (SACCC) electronic data capture system.
Program/Contract:
ProgramContract
Clinical Trials in Organ Transplantation (CTOT) NOVEL THERAPIES OF CHRONIC ALLOGRAFT DYSFUNCTION (CTOT-02)
DOI: 10.21430/M3YRXTC32Z
Subjects: 140
Study PI, contact:
NameOrganizationSite
Mohamed Sayegh Brigham and Women's Hospital Brigham and Women's Hospital
Publications:
Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation.. Journal of the American College of Cardiology Jul 2019. doi: 10.1016/j.jacc.2019.04.056 [Pubmed: 31272550]
Resources:
ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT01278745]
Assays:None
Clinical Assessments:None

SDY1734: Controlled malaria infection in Europeans and Africans
Status: New
Description: LACHMI-001 is a human trial to study immunity against Plasmodium falciparum in a controlled infection setting.
Program/Contract:
ProgramContract
DMID Sanaria Grant Program Genome-Wide Sieve Analysis And Immunological Validation To Identify Targets Of Protective Efficacy In Field Trials Of A Whole-Organism Malaria Vaccine
DOI: 10.21430/M3UL8417LG
Subjects: 25
Study PI, contact:
NameOrganizationSite
Maria Yazdanbakhsh Department of Parasitology, LUMC n/a
Publications:
Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon.. The American journal of tropical medicine and hygiene Feb 2018. doi: 10.4269/ajtmh.17-0343 [Pubmed: 29260650]
Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity.. Nature immunology May 2021. doi: 10.1038/s41590-021-00911-7 [Pubmed: 33888898]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/show/NCT02237586]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 75
Flow Cytometry 144
RNA sequencing 75
Clinical Assessments:None

SDY1768: Evolutionary transcriptomics implicates HAND2
Status: New
Description: The developmental origins and evolutionary histories of cell types, tissues, and organs contribute to the ways in which their dysfunction produces disease. In mammals, the nature, development and evolution of maternal-fetal interactions likely influence diseases of pregnancy. Here we show genes that evolved expression at the maternal-fetal interface in Eutherian mammals play essential roles in the evolution of pregnancy and are associated with immunological disorders and preterm birth. Among these genes is HAND2, a transcription factor that suppresses estrogen signaling, a Eutherian innovation allowing blastocyst implantation. We found dynamic HAND2 expression in the decidua throughout the menstrual cycle and pregnancy, gradually decreasing to a low at term. HAND2 regulates a distinct set of genes in endometrial stromal fibroblasts including IL15, a cytokine also exhibiting dynamic expression throughout the menstrual cycle and gestation, promoting migration of natural killer cells and extravillous cytotrophoblasts. We demonstrate that HAND2 promoter loops to an enhancer containing SNPs implicated in birth weight and gestation length regulation. Collectively, these data connect HAND2 expression at the maternal-fetal interface with evolution of implantation and gestational regulation, and preterm birth.
Program/Contract:
ProgramContract
March of Dimes March of Dimes
DOI: 10.21430/M3TSWJOVTM
Subjects: 1
Study PI, contact:
NameOrganizationSite
Vincent Lynch Uchicago Uchicago
Publications:
Evolutionary transcriptomics implicates HAND2 in the origins of implantation and regulation of gestation length.. eLife Feb 2021. doi: 10.7554/eLife.61257 [Pubmed: 33522483]
Resources:
paper_link https://elifesciences.org/articles/61257]
PRJNA648914 (GSE155170, multi-species) https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA648914]
GSE15570 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155170]
PRJNA649314 (GSE155322) https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA649314]
GSE155322 (Human cell line) https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155322]
IL15 data of pregnant human decidua https://www.proteinatlas.org/ENSG00000164136-IL15/tissue]
HAND2 data of pregnant human decidua https://www.proteinatlas.org/ENSG00000164107-HAND2/tissue]
PRJDB1934 data (tammar wallabies) https://www.omicsdi.org/dataset/omics_ena_project/PRJDB1934]
all_results zip file https://cdn.elifesciences.org/articles/61257/elife-61257-supp-v1.zip]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 12
Clinical Assessments:None

SDY1769: Maternal and Infant Immune Repertoire Sequencing in PPROM study
Status: New
Description: To identify distinct features of immunoglobulin and T-cell receptor development in Preterm labor, the study analyzed T-cell receptor beta chain (TCR-?) and immunoglobulin heavy chain (IgH) diversity, CDR3 lengths, clonal sharing, and preferential usage of variable (V), diversity (D), and joining (J) gene segments. Additionally, the rates of somatic hypermutation (SHM) in IgH were studied. Overall, the cord blood IgH repertoires had significantly (padj < 0.05) lower rates of SHM and both TCR-? and IgH repertoires had shorter CDR3s compared to maternal blood. From the comparative analysis of term vs PPROM cord blood samples, RESULTs 1) CDR3 lengths correlated with gestational age, with the shorter CDR3s in preterm neonates suggesting a `less developed? repertoire. 2) Preterm cord blood displayed preferential usage of a number of V genes and J genes. 3) the term maternal repertoires displayed significant preferential usage of TRBV7-8 compared to preterm maternal repertoires. 4) Significantly higher prevalence of convergent clones between mother/baby pairs in preterm pregnancies. Together, these results suggest the repertoire of preterm infants displays a combination of immature features yet preferential use of particular genes and convergence with maternal TCR-? clones. While the higher TCR-? diversity might reflect less clonal expansion, the higher clonal convergence between mothers and infants in PTL could represent mother and fetus both responding to a shared stimulus like an infection. These data provide a detailed analysis of the maternal-fetal immune repertoire in term and preterm patients, and contribute to a better understanding of neonate immune repertoire development and potential changes associated with preterm labor
Program/Contract:
ProgramContract
March of Dimes March of Dimes
DOI: 10.21430/M3GUQMUDWL
Subjects: 48
Study PI, contact:
NameOrganizationSite
Marina Sirota University of California, San Francisco Institute for Computational Health Sciences
Publications:None
Resources:
preprint_paper https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3793962]
Assays:
Assay TypeNumber of Exp. Samples
Sequencing 96
Clinical Assessments:None

SDY1772: Proteomic Signatures Predict Preeclampsia in Individual Cohorts but not Across Cohorts
Status: New
Description: Early identification of pregnant women at risk for preeclampsia (PE) is important. The study aimed to establish generalizability of quantitative analyses of plasma proteins (using SomaLogic multiplex aptamer-based platform) in two cohorts (Stanford, Detroit). A second aim was to examine the generalizability of protein signatures predictive of gestational age (GA) in uncomplicated pregnancies in the same cohorts to contrast physiological and pathological pregnancy outcomes. Serial blood samples were collected during the first, second, and third trimesters in 18 women who developed PE and 18 women with uncomplicated pregnancies (Stanford cohort). The second cohort (Detroit), used for comparative analysis, consisted of 76 women with PE and 90 women with uncomplicated pregnancies. Multivariate analyses were applied to infer predictive and cohort-specific proteomic models, which were then tested in the alternate cohort. Gene ontology (GO) analysis was performed to identify biological processes that were over-represented among top-ranked proteins associated with PE. Results: The model derived in the Stanford cohort was highly significant (p?=?3.9E?15) and predictive (AUC = 0.96), but failed validation in the Detroit cohort (p?=?9.7E?01, AUC = 0.50). The similarly result was for the Detroit cohort. By contrast, proteomic models predicting GA were readily validated across the two cohorts, indicating that the proteomic assay performed well enough to infer a generalizable model across studied cohorts. The study highlighted the need for performing such studies in diverse and well-phenotyped patient populations that are large enough to characterize subsets of patients with shared pathophysiologies to then derive subset-specific signatures of sufficient predictive power
Program/Contract:
ProgramContract
March of Dimes March of Dimes
DOI: 10.21430/M324Y3362V
Subjects: 202
Study PI, contact:
NameOrganizationSite
Martin Angst Stanford University School of Medicine
Publications:
Proteomic signatures predict preeclampsia in individual cohorts but not across cohorts - implications for clinical biomarker studies.. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians Mar 2021. doi: 10.1080/14767058.2021.1888915 [Pubmed: 33653202]
Resources:
raw_data https://figshare.com/articles/Proteomic_Models_in_Preeclampsia/7962998]
paper_link https://www.tandfonline.com/doi/full/10.1080/14767058.2021.1888915]
Assays:
Assay TypeNumber of Exp. Samples
SOMAscan 764
Clinical Assessments:None

SDY404: Immunologic and genomic signatures of influenza vaccine response - 2011 (see companion studies SDY63, SDY400, SDY520)
Status: Updated
Description: Project 1: Immunologic and genomic signatures of influenza vaccine response - year2 2011
Program/Contract:
ProgramContract
Human Immunology Project Consortium (HIPC) RFA-AI-14-007, RFA-AI-09-040 Defining signatures for immune responsiveness by functional systems immunology HIPC1
DOI: 10.21430/M3GWQRC8DT
Subjects: 72
Study PI, contact:
NameOrganizationSite
David Hafler Yale Yale
Publications:
Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults.. The Journal of infectious diseases Apr 2015. doi: 10.1093/infdis/jiu573 [Pubmed: 25367297]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 2062
Hemagglutination Inhibition 138
Mass Spectrometry 1086
Transcription profiling by array 512
Clinical Assessments:None

SDY1469: B-cell Immunity to Influenza (SLVP017) 2011
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium (HIPC) RFA-AI-14-007, RFA-AI-09-040 Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3HXQPVM9E
Subjects: 22
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford University
Publications:
The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system.. Scientific data Oct 2019. doi: 10.1038/s41597-019-0213-4 [Pubmed: 31636302]
Resources:
CliicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03020498]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 46
Hemagglutination Inhibition 171
Luminex xMAP 112
Clinical Assessments:None
Back to top